Inclusion Criteria:

• The patient (and/or their parent/legal guardian)is willing and able to provide signed informed consent prior to any study-related procedures to be performed.
• The patient is 16 to 65 years old at the time of randomization.
• The patient has a conformed diagnosis of Gaucher Disease type 1 confirmed
• Male patients agree to use a medically accepted method of contraception throughout the study.
• Female patients of childbearing potential must have a documented negative pregnancy test prior to dosing. In addition all female patients of childbearing potential must use a medically accepted form of contraception throughout the study.

Exclusion Criteria:

• The patient has had a partial or total splenectomy.
• The patient has received pharmacological chaperons or miglustat within 6 months prior to randomization
• The patient has received enzyme replacement therapy within 12 months prior to randomization.
• The patient has type 2 or 3 Gaucher Disease or is suspected of having type 3 Gaucher Disease
• The patient has any clinically significant disease, other than Gaucher Disease, including cardiovascular, renal, hepatic. gastrointestinal (GI), Pulmonary, neurologic, endocrine, metabolic, (e.g. hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illness that may confound the study results, or, on the opinion of the investigator, may preclude participation in the study.
• Tha patient has tested positive for the human immunodeficiency virus (HIV)antibody, Hepatitis C antibody, or Hepatitis B surface antigen.
• The patient has received an investigational product within 30 days prior to randomization.
• The patient is pregnant or lactating.